Biology & biomedicine Technological offers
Test for the diagnosis of P. aeruginosa infections by detecting its communication molecules
- Details
- Category: Technological offers
-
10 Jul 2020
The CSIC has developed an immunochemical technique for the diagnosis of Pseudomonas aeruginosa infections. It detects the main signalling molecules that the bacteria use to communicate (Quorum Sensing). The test is very specific and has high sensitivity, as well as a high capacity for sample processing, which ensures diagnostic efficiency. It can also be easily implemented on point-of-care (PoC) devices.
New method for a controlled release of ophthalmic drugs
- Details
- Category: Technological offers
-
30 Jun 2020
Scientists at the CSIC and the University of Zaragoza have developed a new formulation to achieve a controlled and sustained release of different drugs inside the eyeball. Industrial partners from the ophthalmic or pharmaceutical industry are being sought to collaborate through a patent licence agreement.
Monitoring mitochondria of living cells to diagnose cancer and other diseases
- Details
- Category: Technological offers
-
16 Dec 2019
Scientists from the Institute of Organic Chemistry of the CSIC in Madrid have developed the first fluorescent probe to be introduced in the mitochondria to monitor its function in living cells. A discovery that can have applications in the diagnosis and treatment of pathologies such as cancer, heart disease or diabetes, as well as other mitochondrial diseases.
Cell stimulation device for use in medical prostheses
- Details
- Category: Technological offers
-
18 Dec 2019
Scientists at the Microelectronics Institute of Barcelona have developed a device based on nanogenerators for the electrical stimulation of cells, without the need of bulky electrodes or instruments. The advancement has applications in health for bone regeneration in prostheses or the rehabilitation of muscular atrophy.
Synthetic peptides for fighting metastasis related to the interleukin receptor IL13Rα2
- Details
- Category: Technological offers
-
10 Dec 2019
The CSIC has developed a peptide capable of inhibiting the signaling of interleukin 13 mediated by the IL13Rα2 alpha receptor, one of the pathways that contribute metastasis according to recent studies. The synthetic peptide, alone or encapsulated, could be used for the control of metastasis of colon cancer and other tumours such as glioblastoma, as well as in pathologies such as asthma, atopic dermatitis or fibrosis, related to the same receptor, although more assays are required to confirm its efectivity in humans.
